Indication
Celldemic is indicated for active immunisation against H5N1 subtype of Influenza A virus in adults and infants from 6 months of age and above. Celldemic should be used in accordance with official recommendations.
Loading your page…
Loading your page…
Influenza, Human
Marketing Authorisation Holder: Seqirus Netherlands B.V.
EMA Authorisation: 19/04/2024
INN: zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)
AI Drug & Interaction Analysis
Free account required
Ask Osler about Celldemic: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.